Breaking Finance News

Zacks Investment Research announced InVitae Corp (NASDAQ:NVTA), boosting its stock price target to $8.75 today

Just yesterday InVitae Corp (NASDAQ:NVTA) traded 6.29% higher at $7.77. InVitae Corp’s 50-day moving average is $8.19 and its 200-day moving average is $8.83. The last stock price is down -12.05% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 89,732 shares of NVTA traded hands, up from an average trading volume of 87,443

In a report released on 10/15/2016 Zacks Investment Research increased the stock price target of InVitae Corp (NASDAQ:NVTA) to $8.75 reporting a possible upside of 0.13%.

Recent Performance Chart

InVitae Corp (NASDAQ:NVTA)

InVitae Corp has 52 week low of $5.66 and a 52 week high of $11.85 and has a market capitalization of $0.

In addition to Zacks Investment Research reporting its stock price target, a total of 2 brokerages have issued a ratings update on the company. The average stock price target is $10.00 with 0 brokerages rating the stock a strong buy, 2 brokerages rating the stock a buy, 2 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.

Brief Synopsis On InVitae Corp (NASDAQ:NVTA)

Invitae Corporation (Invitae) utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. The Company's laboratory is located in San Francisco, California. The Company's product is an assay of over 600 genes that can be used for multiple indications. The test includes multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders and other hereditary conditions. The Company offers panels for over 120 conditions in hereditary cancer, cardiology, neuromuscular, pediatric and rare diseases. The Company offers full gene sequencing and deletion/duplication analysis as a standard for all of its tests. It has developed an offering that enables healthcare professionals to customize a test and receive test results at requisition.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *